Guillain-Barré syndrome after COVID-19 in Japan

Hirayama, Takehisa; Hongo, Yu; Kaida, Kenichi; Kano, Osamu

doi:10.1136/bcr-2020-239218

Cited by 51 publications

(23 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A patient with MFS had mild symptoms and did not receive any treatment [ 12 ]. One patient had an excellent modified Erasmus GBS Outcome Score (mEGOS), and so did not receive treatment [ 13 ]. One more patient was symptomatically treated with acetaminophen and had a complete recovery [ 14 ].…”

Section: Resultsmentioning

confidence: 99%

Guillain-Barré Syndrome in the COVID-19 Pandemic

Tawakul

Al-Doboke

Altayyar

et al. 2021

Neurology International

View full text Add to dashboard Cite

There have been several reported cases of severe acute respiratory syndrome (SARS-CoV-2) infection that were associated with an increased incidence of neurological manifestations, including Guillain–Barré syndrome (GBS). This review aims to present information on the reports of GBS associated with coronavirus disease 2019 (COVID-19) infection. Our review is retrospective work examining articles published from the 1 April 2020 to the 8 May 2021 in the English language. We used the diagnostic criteria and classification published by the National Institute of Neurological Disorders and Stroke and Brighton Collaboration. GBS is usually a postinfectious syndrome, but GBS in the COVID-19 pandemic also takes on a para-infectious profile. In the reports, the genetic factor has a role in developing GBS in some patients. In conclusion, the association between COVID-19 and GBS is not very clear. Still, one mechanism is strongly associated with COVID-19 and immune-mediated neurological complications, which is molecular mimicry between SARS-CoV-2 and human autoantigens.

show abstract

Section: Resultsmentioning

confidence: 99%

Guillain-Barré Syndrome in the COVID-19 Pandemic

Tawakul

Al-Doboke

Altayyar

et al. 2021

Neurology International

View full text Add to dashboard Cite

show abstract

“…After thorough literature review, we found a substantial number of reported cases and case series of Covid-19 infection presented with GBS. Table 1 summarizes demographic, type of relationship with Covid-19, clinical and GBS sub-types, response to specific GBS treatment, and outcome of different GBS cases who presented in concurrent with Covid 19 infection [[ [3] , [4] , [5] , [6] , [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] ],[ [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] , [67] ...…”

Section: Discussionmentioning

confidence: 99%

“…Common neurological symptoms of COVID-19 are headache, dizziness, dysgeusia/ageusia, hyposmia/anosmia, seizure, stroke, and encephalopathy [ 2 ]. There have been reported cases of Guillain-Barré Syndrome (GBS) associated with COVID-19 from different parts of the world [[ [3] , [4] , [5] , [6] , [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] ],[ [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] , [67] , [68] ,…”

Section: Introductionmentioning

confidence: 99%

COVID-19 infection presented as Guillain-Barre Syndrome: Report of two new cases and review of 116 reported cases and case series

Elzouki¹,

Osman²,

Ahmed³

et al. 2021

Travel Medicine and Infectious Disease

View full text Add to dashboard Cite

Background /Aims: Corona virus disease 2019 (COVID 19) is a pandemic infectious disease of 2020, which often presents with respiratory and gastrointestinal symptoms. The behavior of the virus and its full clinical picture has not been fully studied yet. Many case reports and case series have been running in order to elaborate different presentations and associations. Pulmonary and gastrointestinal features of COVID-19 infection are well outlined; however, neurological manifestations are less defined. Case presentation We report two adult cases of COVID-19 infection presented with acute Guillain-Barre Syndrome (GBS), and a literature review on the causal association between COVID-19 and GBS. Conclusion Our two case reports in addition to literature review of 116 published cases may help offer insight into the clinical course of COVID-19 infection. Our two COVID-19 patients presented with neurological manifestations of GBS which were not preceded with any respiratory, gastrointestinal or other systemic infection. This leads us to raise the possibility of establish direct causal association between COVID-19 infection and GBS. Physicians should have high clinical suspicions when encounter GBS patient during the current COVID-19 pandemic and consider co-existence of COVID-19 infection that may warrant SARS-CoV-2 testing, isolation precautions, and specific treatment for Covid-19 infection.

show abstract

“…As in GBS associated with Zika virus infection, electrophysiological features of GBS associated with COVID‐19 are usually suggestive of demyelination compatible with those of AIDP 34–36 . However, some patients with AMAN or acute motor sensory axonal neuropathy have also been reported 13,34,36,37 . According to a systematic literature review from January to June 2020, the mean interval between the onset of COVID‐19 and GBS symptoms was 11.5 days 35 .…”

Section: Introductionmentioning

confidence: 99%

Emerging infectious diseases, vaccines and Guillain–Barré syndrome

Koike

Katsuno

2021

Clinical & Exp Neuroim

View full text Add to dashboard Cite

The recent outbreak of Zika virus infection increased the incidence of Guillain–Barré syndrome (GBS). Following the first reported case of GBS after Zika virus infection in 2013, there has been a considerable increase in the incidence of GBS in endemic countries, such as French Polynesia and Latin American countries. The association between coronavirus disease 2019 (COVID‐19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), and GBS is another emerging research hotspot. Electrophysiological studies have suggested that GBS patients associated with Zika virus infection or COVID‐19 tend to manifest acute inflammatory demyelinating polyneuropathy, rather than acute motor axonal neuropathy (AMAN). Causative autoantibodies, such as anti‐ganglioside antibodies in AMAN associated with Campylobacter jejuni infection, have not been identified in GBS associated with these emerging infectious diseases. Nevertheless, recent studies suggested molecular mimicry between these viruses and human proteins related to GBS. Recent studies have shown the efficacy of new vaccines, containing artificial messenger RNA encoding the spike protein of SARS‐CoV‐2, against COVID‐19. These vaccines are now available in many countries and massive vaccination campaigns are currently ongoing. Although there are long‐standing concerns about the increased risk of GBS after inoculation of conventional vaccines, the risk of GBS is not considered a legitimate reason to limit administration of currently available vaccines, because the benefits outweigh the risks.

show abstract

Guillain-Barré syndrome after COVID-19 in Japan

Cited by 51 publications

References 23 publications

Guillain-Barré Syndrome in the COVID-19 Pandemic

Guillain-Barré Syndrome in the COVID-19 Pandemic

COVID-19 infection presented as Guillain-Barre Syndrome: Report of two new cases and review of 116 reported cases and case series

Emerging infectious diseases, vaccines and Guillain–Barré syndrome

Contact Info

Product

Resources

About